0.2876
price up icon13.14%   0.035
after-market Dopo l'orario di chiusura: .29 0.0024 +0.83%
loading
Precedente Chiudi:
$0.2526
Aprire:
$0.254
Volume 24 ore:
1.08M
Relative Volume:
0.06
Capitalizzazione di mercato:
$18.00M
Reddito:
$1.16M
Utile/perdita netta:
$-37.28M
Rapporto P/E:
-0.4959
EPS:
-0.58
Flusso di cassa netto:
$-33.81M
1 W Prestazione:
+5.93%
1M Prestazione:
+14.92%
6M Prestazione:
+31.10%
1 anno Prestazione:
-91.59%
Intervallo 1D:
Value
$0.254
$0.2899
Intervallo di 1 settimana:
Value
$0.2426
$0.2899
Portata 52W:
Value
$0.1406
$3.47

Glycomimetics Inc Stock (GLYC) Company Profile

Name
Nome
Glycomimetics Inc
Name
Telefono
240-243-1201
Name
Indirizzo
9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Name
Dipendente
35
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-04
Name
Ultimi documenti SEC
Name
GLYC's Discussions on Twitter

Confronta GLYC con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
GLYC
Glycomimetics Inc
0.2876 18.00M 1.16M -37.28M -33.81M -0.58
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
438.40 113.67B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
683.08 74.97B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
665.68 40.50B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
277.16 35.95B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
120.88 29.63B 3.30B -501.07M 1.03B -2.1146

Glycomimetics Inc Stock (GLYC) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-07-26 Downgrade TD Cowen Buy → Hold
2023-12-22 Iniziato CapitalOne Overweight
2021-11-12 Aggiornamento Jefferies Hold → Buy
2019-11-14 Iniziato ROTH Capital Buy
2019-08-05 Downgrade Jefferies Buy → Hold
2019-08-05 Downgrade Piper Jaffray Overweight → Neutral
2019-08-05 Downgrade SunTrust Buy → Hold
2019-04-12 Iniziato Piper Jaffray Overweight
2018-12-18 Iniziato H.C. Wainwright Buy
2016-07-26 Iniziato SunTrust Buy
2015-03-17 Reiterato Stifel Buy
Mostra tutto

Glycomimetics Inc Borsa (GLYC) Ultime notizie

pulisher
Jan 25, 2025

GlycoMimetics (NASDAQ:GLYC) Now Covered by Analysts at StockNews.com - Defense World

Jan 25, 2025
pulisher
Jan 20, 2025

Should You Buy GlycoMimetics (GLYC) Ahead of Earnings? - MSN

Jan 20, 2025
pulisher
Jan 17, 2025

GlycoMimetics (NASDAQ:GLYC) Coverage Initiated at StockNews.com - Defense World

Jan 17, 2025
pulisher
Jan 15, 2025

GlycoMimetics and Crescent Biopharma Update Investor Presentation in Connection with Proposed Merger - Defense World

Jan 15, 2025
pulisher
Jan 14, 2025

GlycoMimetics and Crescent Biopharma Announce Merger Plans - Yahoo Finance

Jan 14, 2025
pulisher
Jan 13, 2025

Avacta Appoints Brian Hahn as Chief Financial Officer - The Manila Times

Jan 13, 2025
pulisher
Jan 13, 2025

Avacta Appoints Brian Hahn as Chief Financial Officer - GlobeNewswire Inc.

Jan 13, 2025
pulisher
Jan 09, 2025

StockNews.com Begins Coverage on GlycoMimetics (NASDAQ:GLYC) - Defense World

Jan 09, 2025
pulisher
Jan 01, 2025

GlycoMimetics (NASDAQ:GLYC) Earns Sell Rating from Analysts at StockNews.com - Defense World

Jan 01, 2025
pulisher
Dec 30, 2024

Is It Time For Me To Buy GlycoMimetics Inc (NASDAQ: GLYC) Stock Now? - Stocks Register

Dec 30, 2024
pulisher
Dec 27, 2024

GlycoMimetics Receives Extension Notice from Nasdaq Regarding Minimum Bid Price ComplianceOn December 19, 2024, GlycoMimetics, Inc. (NASDAQ: GLYC) disclosed in an 8-K filing with the Securities and Exchange Commission that it had received an e - Defense World

Dec 27, 2024
pulisher
Dec 19, 2024

GlycoMimetics, Inc. announced that it expects to receive $200 million in funding - Marketscreener.com

Dec 19, 2024
pulisher
Dec 16, 2024

GlycoMimetics (NASDAQ:GLYC) Now Covered by StockNews.com - Defense World

Dec 16, 2024
pulisher
Dec 02, 2024

GlycoMimetics skyrockets on buyout deal - MSN

Dec 02, 2024
pulisher
Nov 27, 2024

Logos Global Management LP Acquires 5 Million Shares in GlycoMim - GuruFocus.com

Nov 27, 2024
pulisher
Nov 24, 2024

StockNews.com Initiates Coverage on GlycoMimetics (NASDAQ:GLYC) - Defense World

Nov 24, 2024
pulisher
Nov 14, 2024

GlycoMimetics: Q3 Earnings Snapshot - Darien Times

Nov 14, 2024
pulisher
Nov 12, 2024

Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024 - Quantisnow

Nov 12, 2024
pulisher
Nov 12, 2024

Crescent Biopharma to Showcase Cancer Drug Pipeline at Jefferies Healthcare Conference - StockTitan

Nov 12, 2024
pulisher
Nov 09, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ZUO, PFIE, GLYC on Behalf of Shareholders - The Malaysian Reserve

Nov 09, 2024
pulisher
Nov 08, 2024

Finansavisen - Finansavisen

Nov 08, 2024
pulisher
Nov 07, 2024

RA Capital Management's Strategic Acquisition of GlycoMimetics I - GuruFocus.com

Nov 07, 2024
pulisher
Nov 06, 2024

GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting - BioSpace

Nov 06, 2024
pulisher
Nov 06, 2024

Top 3 Penny Stocks to Watch Today – October 31, 2024 - The Global Domains News

Nov 06, 2024
pulisher
Nov 06, 2024

Shares of Biotech Company Up Over 100% Premarket Following Merger & Funding Announcement - MSN

Nov 06, 2024
pulisher
Nov 05, 2024

INVESTIGATION ALERT: The M&A Class Action Firm Investigates the Merger of GlycoMimetics, Inc. – GLYC - WICZ

Nov 05, 2024
pulisher
Nov 05, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALTR, PFIE, GLYC on Behalf of Shareholders - Marketscreener.com

Nov 05, 2024
pulisher
Nov 05, 2024

What Do Wall Street Analysts Think About GlycoMimetics Inc (NASDAQ: GLYC) Stock? - Stocks Register

Nov 05, 2024
pulisher
Nov 03, 2024

INVESTIGATION ALERT: The M&A Class Action Firm Investigates the Merger of GlycoMimetics, Inc.GLYC - PR Newswire

Nov 03, 2024
pulisher
Nov 01, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates USAP, ALTR, GLYC on Behalf of Shareholders - The Malaysian Reserve

Nov 01, 2024
pulisher
Nov 01, 2024

GlycoMimetics’ Acquisition of Crescent Biopharma - Global Legal Chronicle

Nov 01, 2024
pulisher
Oct 31, 2024

GlycoMimetics, Canaan, PayPal: 3 Stocks Retail Is Most Bullish On Today - MSN

Oct 31, 2024
pulisher
Oct 31, 2024

GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc.GLYC - Business Wire

Oct 31, 2024
pulisher
Oct 31, 2024

3 Penny Stocks to Watch Now, 10/31/24 - TipRanks

Oct 31, 2024
pulisher
Oct 31, 2024

GlycoMimetics Announces Merger Agreement with Crescent Biopharma: A Look at the Details - Defense World

Oct 31, 2024
pulisher
Oct 30, 2024

GlycoMimetics To Acquire Crescent Biopharma - FinSMEs

Oct 30, 2024
pulisher
Oct 30, 2024

Kuehn Law Encourages PFIE, GLYC, RVNC, and RCM Investors to Contact Law Firm - Morningstar

Oct 30, 2024
pulisher
Oct 30, 2024

GlycoMimetics soars on news of M&A deal with Crescent Biopharma - The Pharma Letter

Oct 30, 2024
pulisher
Oct 30, 2024

GlycoMimetics Announces Merger with Crescent Biopharma - Yahoo Finance

Oct 30, 2024
pulisher
Oct 30, 2024

GlycoMimetics Insider Confidence Rewarded, Stock Hits US$11m Market Cap - Simply Wall St

Oct 30, 2024
pulisher
Oct 30, 2024

Biotech Up Over +100% Premarket Following Merger And Funding Announcement - MSN

Oct 30, 2024
pulisher
Oct 29, 2024

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire

Oct 29, 2024
pulisher
Oct 29, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE, CPTN, GLYC, ARC on Behalf of Shareholders - GlobeNewswire

Oct 29, 2024
pulisher
Oct 29, 2024

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Profire Energy, Inc. (Nasdaq – PFIE), Cepton, Inc. (Nasdaq – CPTN), GlycoMimetics, Inc. (Nasdaq – GLYC), ARC Document Solutions, Inc. (NYSE – ARC) - ForexTV.com

Oct 29, 2024

Glycomimetics Inc Azioni (GLYC) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$352.30
price down icon 5.46%
$41.04
price up icon 0.79%
$22.36
price up icon 3.33%
$5.41
price up icon 2.77%
biotechnology ONC
$226.89
price up icon 0.17%
$120.88
price down icon 0.23%
Capitalizzazione:     |  Volume (24 ore):